Genmab A/S Capital Raise Sparks Market Rally & Analyst Buy Signals
Genmab’s May 2026 capital increase sparks a sharp drop, yet analysts stay bullish—target prices around 2 200 DKK and buy ratings keep the stock attractive.
2 minutes to read
Genmab
Genmab Q1 Results: Share Recovery, Market Resilience, & Future Growth in Biotech
Genmab’s latest quarterly results reveal a resilient biotech firm on track to expand its antibody cancer therapies, showcasing solid growth and future potential.
2 minutes to read
Genmab Stock Soars: Deutsche Bank Boosts Target to 2,400 DKK Amid Strong Cancer‑Therapy Growth
Genmab’s 2025 stock outlook: strong market cap, bullish price target, and resilient biotech growth despite no new announcements.
2 minutes to read
Genmab’s Momentum in Antibody-Therapeutics: Strong Trial Data and Strategic Moves Amid Market Volatility
Genmab A/S, a Danish biotechnology firm, continues to demonstrate momentum in the antibody-therapeutics market, driven by positive trial data and strategic growth initiatives, despite a recent dip in share price due to market volatility.
3 minutes to read